News

Zacks Investment Research on MSN8d
Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi
Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi ...
Leqembi®âˆ‡ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early ...
PharmiWeb9d
Leqembi® (lecanemab) is the First Medicine that…
Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...